Journal List > Korean J Gastroenterol > v.60(4) > 1007003

TOOLS
Jung, Hong, Jo, Jeon, Cho, Lee, Lee, Park, Shin, Lee, Han, and The Korean Society of Neurogastroenterology and Motility: Updated Guidelines 2012 for Gastroesophageal Reflux Disease
Review Article
The Korean Journal of Gastroenterology

The Korean Journal of Gastroenterology 2012; 60(4): 195-218.

Published online: 20 October 2012

DOI: https://doi.org/10.4166/kjg.2012.60.4.195

Updated Guidelines 2012 for Gastroesophageal Reflux Disease

Hye-Kyung Jung, Su Jin Hong1, Yunju Jo2, Seong Woo Jeon3, Yu Kyung Cho4, Kwang Jae Lee5, Joon Seong Lee1, Hyo Jin Park6, Ein Soon Shin7, 8, Sun Hee Lee9, Sang-Uk Han10; The Korean Society of Neurogastroenterology and Motility

Department of Internal Medicine, Ewha Womans University School of Medicine, Seoul, Korea.

1Department of Internal Medicine, Soonchunhyang University College of Medicine, Seoul, Korea.

2Department of Internal Medicine, Eulji University School of Medicine, Seoul, Korea.

3Department of Internal Medicine, Kyungpook National University School of Medicine, Daegu, Korea.

4Department of Internal Medicine, The Catholic University of Korea College of Medicine, Seoul, Korea.

5Department of Gastroenterology, Ajou University School of Medicine, Suwon, Korea.

6Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.

7Department of Preventive Medicine and Public Health, Ajou University School of Medicine, Suwon, Korea.

8Steering Committee for Clinical Practice Guideline, Korean Academy of Medical Science, Seoul, Korea.

9Department of Preventive Medicine, Ewha Womans University School of Medicine, Seoul, Korea.

10Department of Surgery, Ajou University School of Medicine, Suwon, Korea.

Correspondence to: Kwang Jae Lee, Department of Gastroenterology, Ajou University School of Medicine, 206 WorldCup-ro, Yeongtong-gu, Suwon 443-749, Korea. Tel: +82-31-219-6939, Fax: +82-31-219-5999, kjl@ajou.ac.kr

Received 3 July 2012       Revised 22 July 2012       Accepted 22 July 2012

Copyright © 2012 The Korean Society of Gastroenterology

(open-access):

This is an open access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

In 2010, a Korean guideline for the management of gastroesophageal reflux disease (GERD) was made by the Korean Society of Neurogastroenterology and Motility, in which the definition and diagnosis of GERD were not included. The aim of this guideline was to update the clinical approach to the diagnosis and management of GERD in adult patients. This guideline was developed by the adaptation process of the ADAPTE framework. Twelve guidelines were retrieved from initial queries through the Appraisal of Guidelines for Research & Evaluation II process. Twenty-seven statements were made as a draft and revised by modified Delphi method. Finally, 24 consensus statements for the definition (n=4), diagnosis (n=7) and management (n=13) of GERD were developed. Multidisciplinary experts participated in the development of the guideline, and the external review of the guideline was conducted at the finalization phase.

Keywords: Gastroesophageal reflux disease, Guidelines, Adaptation

Figures and Tables

Fig. 1
Flowchart of study selection. CMA, Canadian Medical Association; OTC, over-the-count only care.
kjg-60-195-g001
Fig. 2
Appraisal results of candidate guidelines by AGREE II. Selected guidelines number; 1, Genval workshop; 2, Digestive Health Foundation of Gastroenterogical Society of Australia; 3, International Multidisciplinary Workshop; 4, Canadian consensus; 5, ACG, American Gastroenterology Association; 6, Advancing Excellence in Healthcare Research and Quality (AHRQ) comparative review ; 7, Montreal consensus; 8, American Gastroenterology Association (AGA) medical position statement on the management of gastroesophageal reflux disease (GERD); 9, Asia-Pacific (AP) consensus on GERD; 10, Brazil GERD guideline; 11, Vevey non-erosive reflux disease (NERD) consensus.
kjg-60-195-g002
Fig. 3
Management of uninvestigated typical reflux symptoms with alarming features. (A) Uninvestigated typical reflux symptoms with alarming features. (B) Uninvestigated typical reflux symptoms without alarming features. EGD, esophagogastroduodenoscopy; NSAIDs, non-steroidal anti-inflammatory drugs; PPI, proton pump inhibitors; RE, reflux esophagitis; Tx, treatment.
kjg-60-195-g003
Fig. 4
Management of uninvestigated atypical reflux symptoms. EGD, esophagogastroduodenoscopy; PPI, proton pump inhibitor; RE, reflux esophagitis; Tx, treatment.
kjg-60-195-g004
Table 1
Data Extraction Form/Evidence Inventory Form for Role of Helicobacter pylori in the Diagnosis of Gastroesophageal Reflux Disease
kjg-60-195-i001

AGA, American Gastroenterology Association; AHRQ, Advancing Excellence in Healthcare Research and Quality; AP, Asia-Pacific consensus; CS, case series study; G, guideline; GERD, gastroesophageal reflux disease; NERD, non-erosive reflux disease; NR, nonsystematic, narrative review; NRCS, non-randomized comparative study; PPI, proton pump inhibitor; RCT, randomized controlled trial; SR/MA, systemic review/meta-analysis.

Table 2
Level of Evidence and Grade of Recommendation
kjg-60-195-i002

RCT, randomized controlled trial.

Table 3
Retrieval of Statements in Adaptation Process
kjg-60-195-i003

AGA, American Gastroenterology Association; AHRQ, Advancing Excellence in Healthcare Research and Quality; APDW, Asia Pacific Digestive Week; GERD, gastroesophageal reflux disease; NERD, non-erosive reflux disease.

Notes

Financial support: This study was partially supported by a grant of the Korea Academy of Medical Society and Korean Society of Neurogastroenterology and Motility.

Conflict of interest: None.

References

1. Rhee PL. Review : Evidence based guideline for diagnosis and treatment: Diagnostic guideline for GERD. Korean J Neurogastroenterol Motil. 2005. 11:5–12.
2. Lee JH, Cho YK, Jeon SW, et al. Korean Society of Neurogastroenterology and Motility. Guidelines for the treatment of gastroesophageal reflux disease. Korean J Gastroenterol. 2011. 57:57–66.
3. Steering Committee for Clinical Practice Guideline. Adaptation process for developing Korean clinical practice guidelines. 2011. 1st ed. Seoul: Minister of Health & Welfare · Korean Academy of Medical Sciences.
4. Deeks JJ, Dinnes J, D'Amico R, et al. International Stroke Trial Collaborative Group. European Carotid Surgery Trial Collaborative Group. Evaluating non-randomised intervention studies. Health Technol Assess. 2003. 7:iii–iix. 1–173.
5. Guyatt GH, Cook DJ, Jaeschke R, Pauker SG, Schünemann HJ. Grades of recommendation for antithrombotic agents: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest. 2008. 133:6 Suppl. 123S–131S.
6. Schnemann HJ, Oxman AD, Brozek J, et al. GRADE Working Group. Grading quality of evidence and strength of recommendations for diagnostic tests and strategies. BMJ. 2008. 336:1106–1110.
7. Dent J, Brun J, Fendrick A, et al. An evidence-based appraisal of reflux disease management-the Genval Workshop Report. Gut. 1999. 44:Suppl 2. S1–S16.
8. Dimenäs E. Methodological aspects of evaluation of quality of life in upper gastrointestinal diseases. Scand J Gastroenterol Suppl. 1993. 199:18–21.
9. Glise H. Quality of life and cost of therapy in reflux disease. Scand J Gastroenterol Suppl. 1995. 210:38–42.
10. Rush DR, Stelmach WJ, Young TL, et al. Clinical effectiveness and quality of life with ranitidine vs placebo in gastroesophageal reflux disease patients: a clinical experience network (CEN) study. J Fam Pract. 1995. 41:126–136.
11. Glise H, Wiklund I. Measurement of the impact of heartburn and dyspepsia on quality of life. Aliment Pharmacol Ther. 1997. 11:73–77.
12. Dimenäs E, Carlsson G, Glise H, Israelsson B, Wiklund I. Relevance of norm values as part of the documentation of quality of life instruments for use in upper gastrointestinal disease. Scand J Gastroenterol Suppl. 1996. 221:8–13.
13. Armstrong D, Marshall JK, Chiba N, et al. Canadian Association of Gastroenterology GERD Consensus Group. Canadian Consensus Conference on the management of gastroesophageal reflux disease in adults - update 2004. Can J Gastroenterol. 2005. 19:15–35.
14. Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R. Global Consensus Group. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol. 2006. 101:1900–1920.
15. Wiklund I, Carlsson J, Vakil N. Gastroesophageal reflux symptoms and well-being in a random sample of the general population of a Swedish community. Am J Gastroenterol. 2006. 101:18–28.
16. Ronkainen J, Aro P, Storskrubb T, et al. Gastro-oesophageal reflux symptoms and health-related quality of life in the adult general population--the Kalixanda study. Aliment Pharmacol Ther. 2006. 23:1725–1733.
17. Kahrilas PJ, Shaheen NJ, Vaezi MF, et al. American Gastroenterological Association. American Gastroenterological Association Medical Position Statement on the management of gastroesophageal reflux disease. Gastroenterology. 2008. 135:1383–1391.e5.
18. Modlin IM, Hunt RH, Malfertheiner P, et al. Vevey NERD Consensus Group. Diagnosis and management of non-erosive reflux disease--the Vevey NERD Consensus Group. Digestion. 2009. 80:74–88.
19. Fock KM, Talley NJ, Fass R, et al. Asia-Pacific consensus on the management of gastroesophageal reflux disease: update. J Gastroenterol Hepatol. 2008. 23:8–22.
20. Lundell LR, Dent J, Bennett JR, et al. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut. 1999. 45:172–180.
21. Galmiche JP, Clouse RE, Balint A, et al. Functional esophageal disorders. Gastroenterology. 2006. 130:1459–1465.
22. Klauser AG, Schindlbeck NE, Müller-Lissner SA. Symptoms in gastro-oesophageal reflux disease. Lancet. 1990. 335:205–208.
23. Howard PJ, Maher L, Pryde A, Heading RC. Symptomatic gastro-oesophageal reflux, abnormal oesophageal acid exposure, and mucosal acid sensitivity are three separate, though related, aspects of gastro-oesophageal reflux disease. Gut. 1991. 32:128–132.
24. Kim N, Lee SW, Cho SI, et al. H. pylori and Gerd Study Group of Korean College of Helicobacter and Upper Gastrointestinal Research. The prevalence of and risk factors for erosive oesophagitis and non-erosive reflux disease: a nationwide multicentre prospective study in Korea. Aliment Pharmacol Ther. 2008. 27:173–185.
25. Khan M, Santana J, Donnellan C, Preston C, Moayyedi P. Medical treatments in the short term management of reflux oesophagitis. Cochrane Database Syst Rev. 2007. (2):CD003244.
26. Marshall RE, Anggiansah A, Owen WA, Owen WJ. Investigation of oesophageal reflux symptoms after gastric surgery with combined pH and bilirubin monitoring. Br J Surg. 1999. 86:271–275.
27. Okamoto K, Iwakiri R, Mori M, et al. Clinical symptoms in endoscopic reflux esophagitis: evaluation in 8031 adult subjects. Dig Dis Sci. 2003. 48:2237–2241.
28. Kusano M, Shimoyama Y, Sugimoto S, et al. Development and evaluation of FSSG: frequency scale for the symptoms of GERD. J Gastroenterol. 2004. 39:888–891.
29. Jung HK. Epidemiology of gastroesophageal reflux disease in Asia: a systematic review. J Neurogastroenterol Motil. 2011. 17:14–27.
30. Richards H, McConnachie A, Morrison C, Murray K, Watt G. Social and gender variation in the prevalence, presentation and general practitioner provisional diagnosis of chest pain. J Epidemiol Community Health. 2000. 54:714–718.
31. Eslick GD, Jones MP, Talley NJ. Non-cardiac chest pain: prevalence, risk factors, impact and consulting-a population-based study. Aliment Pharmacol Ther. 2003. 17:1115–1124.
32. Locke GR 3rd, Talley NJ, Fett SL, Zinsmeister AR, Melton LJ 3rd. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology. 1997. 112:1448–1456.
33. Gislason T, Janson C, Vermeire P, et al. Respiratory symptoms and nocturnal gastroesophageal reflux: a population-based study of young adults in three European countries. Chest. 2002. 121:158–163.
34. Rey E, Elola-Olaso CM, Rodríguez-Artalejo F, Locke GR 3rd, Díaz-Rubio M. Prevalence of atypical symptoms and their association with typical symptoms of gastroesophageal reflux in Spain. Eur J Gastroenterol Hepatol. 2006. 18:969–975.
35. el-Serag HB, Sonnenberg A. Comorbid occurrence of laryngeal or pulmonary disease with esophagitis in United States military veterans. Gastroenterology. 1997. 113:755–760.
36. Chang AB, Lasserson TJ, Gaffney J, Connor FL, Garske LA. Gastro-oesophageal reflux treatment for prolonged non-specific cough in children and adults. Cochrane Database Syst Rev. 2011. (1):CD004823.
37. So JB, Zeitels SM, Rattner DW. Outcomes of atypical symptoms attributed to gastroesophageal reflux treated by laparoscopic fundoplication. Surgery. 1998. 124:28–32.
38. Kamel PL, Hanson D, Kahrilas PJ. Omeprazole for the treatment of posterior laryngitis. Am J Med. 1994. 96:321–326.
39. Gasiorowska A, Fass R. The proton pump inhibitor (PPI) test in GERD: does it still have a role? J Clin Gastroenterol. 2008. 42:867–874.
40. Numans ME, Lau J, de Wit NJ, Bonis PA. Short-term treatment with proton-pump inhibitors as a test for gastroesophageal reflux disease: a meta-analysis of diagnostic test characteristics. Ann Intern Med. 2004. 140:518–527.
41. Moayyedi P, Axon AT. The usefulness of the likelihood ratio in the diagnosis of dyspepsia and gastroesophageal reflux disease. Am J Gastroenterol. 1999. 94:3122–3125.
42. Peng S, Xiong LS, Xiao YL, et al. Prompt upper endoscopy is an appropriate initial management in uninvestigated chinese patients with typical reflux symptoms. Am J Gastroenterol. 2010. 105:1947–1952.
43. Wu JC, Chan FK, Ching JY, et al. Empirical treatment based on "typical" reflux symptoms is inappropriate in a population with a high prevalence of Helicobacter pylori infection. Gastrointest Endosc. 2002. 55:461–465.
44. Ghoshal UC, Singh R, Chang FY, Hou X, Wong BC, Kachintorn U. Functional Dyspepsia Consensus Team of the Asian Neurogastroenterology and Motility Association and the Asian Pacific Association of Gastroenterology. Epidemiology of uninvestigated and functional dyspepsia in Asia: facts and fiction. J Neurogastroenterol Motil. 2011. 17:235–244.
45. Vakil N, Moayyedi P, Fennerty MB, Talley NJ. Limited value of alarm features in the diagnosis of upper gastrointestinal malignancy: systematic review and meta-analysis. Gastroenterology. 2006. 131:390–401.
46. Sung JJ, Lao WC, Lai MS, et al. Incidence of gastroesophageal malignancy in patients with dyspepsia in Hong Kong: implications for screening strategies. Gastrointest Endosc. 2001. 54:454–458.
47. Holloway RH, Dent J, Narielvala F, Mackinnon AM. Relation between oesophageal acid exposure and healing of oesophagitis with omeprazole in patients with severe reflux oesophagitis. Gut. 1996. 38:649–654.
48. Pandolfino JE, Vakil NB, Kahrilas PJ. Comparison of inter- and intraobserver consistency for grading of esophagitis by expert and trainee endoscopists. Gastrointest Endosc. 2002. 56:639–643.
49. Richter JE. Diagnostic tests for gastroesophageal reflux disease. Am J Med Sci. 2003. 326:300–308.
50. Gonsalves N, Policarpio-Nicolas M, Zhang Q, Rao MS, Hirano I. Histopathologic variability and endoscopic correlates in adults with eosinophilic esophagitis. Gastrointest Endosc. 2006. 64:313–319.
51. Furuta GT, Liacouras CA, Collins MH, et al. First International Gastrointestinal Eosinophil Research Symposium (FIGERS) Subcommittees. Eosinophilic esophagitis in children and adults: a systematic review and consensus recommendations for diagnosis and treatment. Gastroenterology. 2007. 133:1342–1363.
52. Barrett NR. Chronic peptic ulcer of the oesophagus and 'oesophagitis'. Br J Surg. 1950. 38:175–182.
53. Sampliner RE. Practice Parameters Committee of the American College of Gastroenterology. Updated guidelines for the diagnosis, surveillance, and therapy of Barrett's esophagus. Am J Gastroenterol. 2002. 97:1888–1895.
54. Sharma P, McQuaid K, Dent J, et al. AGA Chicago Workshop. A critical review of the diagnosis and management of Barrett's esophagus: the AGA Chicago Workshop. Gastroenterology. 2004. 127:310–330.
55. Wang KK, Sampliner RE. Practice Parameters Committee of the American College of Gastroenterology. Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett's esophagus. Am J Gastroenterol. 2008. 103:788–797.
56. American Gastroenterological Association. Spechler SJ, Sharma P, Souza RF, Inadomi JM, Shaheen NJ. American Gastroenterological Association medical position statement on the management of Barrett's esophagus. Gastroenterology. 2011. 140:1084–1091.
57. Paull A, Trier JS, Dalton MD, Camp RC, Loeb P, Goyal RK. The histologic spectrum of Barrett's esophagus. N Engl J Med. 1976. 295:476–480.
58. Haggitt RC, Tryzelaar J, Ellis FH, Colcher H. Adenocarcinoma complicating columnar epithelium-lined (Barrett's) esophagus. Am J Clin Pathol. 1978. 70:1–5.
59. Smith RR, Hamilton SR, Boitnott JK, Rogers EL. The spectrum of carcinoma arising in Barrett's esophagus. A clinicopathologic study of 26 patients. Am J Surg Pathol. 1984. 8:563–573.
60. Paraf F, Fléjou JF, Pignon JP, Fékété F, Potet F. Surgical pathology of adenocarcinoma arising in Barrett's esophagus. Analysis of 67 cases. Am J Surg Pathol. 1995. 19:183–191.
61. Spechler SJ, Sharma P, Souza RF, Inadomi JM, Shaheen NJ. American Gastroenterological Association. American Gastroenterological Association technical review on the management of Barrett's esophagus. Gastroenterology. 2011. 140:e18–e52.
62. American Gastroenterological Association medical position statement: guidelines on the use of esophageal pH recording. Gastroenterology. 1996. 110:1981.
63. Kahrilas PJ, Shaheen NJ, Vaezi MF. American Gastroenterological Association Institute. Clinical Practice and Quality Management Committee. American Gastroenterological Association Institute technical review on the management of gastroesophageal reflux disease. Gastroenterology. 2008. 135:1392–1413. 413 e1–413 e5.
64. Ward EM, Devault KR, Bouras EP, et al. Successful oesophageal pH monitoring with a catheter-free system. Aliment Pharmacol Ther. 2004. 19:449–454.
65. Pandolfino JE, Richter JE, Ours T, Guardino JM, Chapman J, Kahrilas PJ. Ambulatory esophageal pH monitoring using a wireless system. Am J Gastroenterol. 2003. 98:740–749.
66. Pandolfino JE, Kahrilas PJ. American Gastroenterological Association. AGA technical review on the clinical use of esophageal manometry. Gastroenterology. 2005. 128:209–224.
67. Pandolfino JE, Ghosh SK, Rice J, Clarke JO, Kwiatek MA, Kahrilas PJ. Classifying esophageal motility by pressure topography characteristics: a study of 400 patients and 75 controls. Am J Gastroenterol. 2008. 103:27–37.
68. Ghosh SK, Pandolfino JE, Rice J, Clarke JO, Kwiatek M, Kahrilas PJ. Impaired deglutitive EGJ relaxation in clinical esophageal manometry: a quantitative analysis of 400 patients and 75 controls. Am J Physiol Gastrointest Liver Physiol. 2007. 293:G878–G885.
69. Bredenoord AJ, Weusten BL, Timmer R, Conchillo JM, Smout AJ. Addition of esophageal impedance monitoring to pH monitoring increases the yield of symptom association analysis in patients off PPI therapy. Am J Gastroenterol. 2006. 101:453–459.
70. Sifrim D, Mittal R, Fass R, et al. Review article: acidity and volume of the refluxate in the genesis of gastro-oesophageal reflux disease symptoms. Aliment Pharmacol Ther. 2007. 25:1003–1017.
71. Farré R, van Malenstein H, De Vos R, et al. Short exposure of oesophageal mucosa to bile acids, both in acidic and weakly acidic conditions, can impair mucosal integrity and provoke dilated intercellular spaces. Gut. 2008. 57:1366–1374.
72. Koek GH, Sifrim D, Lerut T, Janssens J, Tack J. Effect of the GABA(B) agonist baclofen in patients with symptoms and duodeno-gastro-oesophageal reflux refractory to proton pump inhibitors. Gut. 2003. 52:1397–1402.
73. Savarino E, Zentilin P, Tutuian R, et al. The role of nonacid reflux in NERD: lessons learned from impedance-pH monitoring in 150 patients off therapy. Am J Gastroenterol. 2008. 103:2685–2693.
74. Bredenoord AJ, Weusten BL, Curvers WL, Timmer R, Smout AJ. Determinants of perception of heartburn and regurgitation. Gut. 2006. 55:313–318.
75. Zerbib F, Duriez A, Roman S, Capdepont M, Mion F. Determinants of gastro-oesophageal reflux perception in patients with persistent symptoms despite proton pump inhibitors. Gut. 2008. 57:156–160.
76. Harvey RF, Gordon PC, Hadley N, et al. Effects of sleeping with the bed-head raised and of ranitidine in patients with severe peptic oesophagitis. Lancet. 1987. 2:1200–1203.
77. Hampel H, Abraham NS, El-Serag HB. Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications. Ann Intern Med. 2005. 143:199–211.
78. Fraser-Moodie CA, Norton B, Gornall C, et al. Weight loss has an independent beneficial effect on symptoms of gastro-oesophageal reflux in patients who are overweight. Scand J Gastroenterol. 1999. 34:337–340.
79. Kjellin A, Ramel S, Rössner S, Thor K. Gastroesophageal reflux in obese patients is not reduced by weight reduction. Scand J Gastroenterol. 1996. 31:1047–1051.
80. Waring JP, Eastwood TF, Austin JM, Sanowski RA. The immediate effects of cessation of cigarette smoking on gastroesophageal reflux. Am J Gastroenterol. 1989. 84:1076–1078.
81. van Pinxteren B, Sigterman KE, Bonis P, Lau J, Numans ME. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev. 2010. (11):CD002095.
82. Galmiche JP, Shi G, Simon B, Casset-Semanza F, Slama A. On-demand treatment of gastro-oesophageal reflux symptoms: a comparison of ranitidine 75 mg with cimetidine 200 mg or placebo. Aliment Pharmacol Ther. 1998. 12:909–917.
83. Komazawa Y, Adachi K, Mihara T, et al. Tolerance to famotidine and ranitidine treatment after 14 days of administration in healthy subjects without Helicobacter pylori infection. J Gastroenterol Hepatol. 2003. 18:678–682.
84. Gotthard R, Bodemar G, Brodin U, Jönsson KA. Treatment with cimetidine, antacid, or placebo in patients with dyspepsia of unknown origin. Scand J Gastroenterol. 1988. 23:7–18.
85. Richter JE, Kahrilas PJ, Johanson J, et al. Esomeprazole Study Investigators. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial. Am J Gastroenterol. 2001. 96:656–665.
86. Bate CM, Griffin SM, Keeling PW, et al. Reflux symptom relief with omeprazole in patients without unequivocal oesophagitis. Aliment Pharmacol Ther. 1996. 10:547–555.
87. Chiba N, De Gara CJ, Wilkinson JM, Hunt RH. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology. 1997. 112:1798–1810.
88. Dean BB, Gano AD Jr, Knight K, Ofman JJ, Fass R. Effectiveness of proton pump inhibitors in nonerosive reflux disease. Clin Gastroenterol Hepatol. 2004. 2:656–664.
89. Richter JE, Campbell DR, Kahrilas PJ, Huang B, Fludas C. Lansoprazole compared with ranitidine for the treatment of nonerosive gastroesophageal reflux disease. Arch Intern Med. 2000. 160:1803–1809.
90. Richter JE, Peura D, Benjamin SB, Joelsson B, Whipple J. Efficacy of omeprazole for the treatment of symptomatic acid reflux disease without esophagitis. Arch Intern Med. 2000. 160:1810–1816.
91. DeVault KR, Castell DO. American College of Gastroenterology. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol. 2005. 100:190–200.
92. Savarino V, Di Mario F, Scarpignato C. Proton pump inhibitors in GORD An overview of their pharmacology, efficacy and safety. Pharmacol Res. 2009. 59:135–153.
93. Peghini PL, Katz PO, Bracy NA, Castell DO. Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors. Am J Gastroenterol. 1998. 93:763–767.
94. Mainie I, Tutuian R, Castell DO. Addition of a H2 receptor antagonist to PPI improves acid control and decreases nocturnal acid breakthrough. J Clin Gastroenterol. 2008. 42:676–679.
95. Rackoff A, Agrawal A, Hila A, Mainie I, Tutuian R, Castell DO. Histamine-2 receptor antagonists at night improve gastroesophageal reflux disease symptoms for patients on proton pump inhibitor therapy. Dis Esophagus. 2005. 18:370–373.
96. Fackler WK, Ours TM, Vaezi MF, Richter JE. Long-term effect of H2RA therapy on nocturnal gastric acid breakthrough. Gastroenterology. 2002. 122:625–632.
97. Vakil N, Guda N, Partington S. The effect of over-the-counter ranitidine 75 mg on night-time heartburn in patients with erosive oesophagitis on daily proton pump inhibitor maintenance therapy. Aliment Pharmacol Ther. 2006. 23:649–653.
98. Xue S, Katz PO, Banerjee P, Tutuian R, Castell DO. Bedtime H2 blockers improve nocturnal gastric acid control in GERD patients on proton pump inhibitors. Aliment Pharmacol Ther. 2001. 15:1351–1356.
99. Wang Y, Pan T, Wang Q, Guo Z. Additional bedtime H2-receptor antagonist for the control of nocturnal gastric acid break-through. Cochrane Database Syst Rev. 2009. (4):CD004275.
100. Hetzel DJ, Dent J, Reed WD, et al. Healing and relapse of severe peptic esophagitis after treatment with omeprazole. Gastroenterology. 1988. 95:903–912.
101. Donnellan C, Sharma N, Preston C, Moayyedi P. Medical treatments for the maintenance therapy of reflux oesophagitis and endoscopic negative reflux disease. Cochrane Database Syst Rev. 2005. (2):CD003245.
102. Niklasson A, Lindström L, Simrén M, Lindberg G, Björnsson E. Dyspeptic symptom development after discontinuation of a proton pump inhibitor: a double-blind placebo-controlled trial. Am J Gastroenterol. 2010. 105:1531–1537.
103. Borch K, Renvall H, Liedberg G. Gastric endocrine cell hyperplasia and carcinoid tumors in pernicious anemia. Gastroenterology. 1985. 88:638–648.
104. Ito T, Jensen RT. Association of long-term proton pump inhibitor therapy with bone fractures and effects on absorption of calcium, vitamin B12, iron, and magnesium. Curr Gastroenterol Rep. 2010. 12:448–457.
105. Insogna KL. The effect of proton pump-inhibiting drugs on mineral metabolism. Am J Gastroenterol. 2009. 104:Suppl 2. S2–S4.
106. Sarkar M, Hennessy S, Yang YX. Proton-pump inhibitor use and the risk for community-acquired pneumonia. Ann Intern Med. 2008. 149:391–398.
107. McCarthy DM. Adverse effects of proton pump inhibitor drugs: clues and conclusions. Curr Opin Gastroenterol. 2010. 26:624–631.
108. Gerson LB, Robbins AS, Garber A, Hornberger J, Triadafilopoulos G. A cost-effectiveness analysis of prescribing strategies in the management of gastroesophageal reflux disease. Am J Gastroenterol. 2000. 95:395–407.
109. Tsai HH, Chapman R, Shepherd A, et al. COMMAND Study Group. Esomeprazole 20 mg on-demand is more acceptable to patients than continuous lansoprazole 15 mg in the long-term maintenance of endoscopy-negative gastro-oesophageal reflux patients: the COMMAND Study. Aliment Pharmacol Ther. 2004. 20:657–665.
110. Scholten T, Dekkers CP, Schütze K, Körner T, Bohuschke M, Gatz G. On-demand therapy with pantoprazole 20 mg as effective long-term management of reflux disease in patients with mild GERD: the ORION trial. Digestion. 2005. 72:76–85.
111. Lind T, Havelund T, Lundell L, et al. On demand therapy with omeprazole for the long-term management of patients with heartburn without oesophagitis--a placebo-controlled randomized trial. Aliment Pharmacol Ther. 1999. 13:907–914.
112. Talley NJ, Lauritsen K, Tunturi-Hihnala H, et al. Esomeprazole20 mg maintains symptom control in endoscopy-negative gastro-oesophageal reflux disease: a controlled trial of 'on-demand' therapy for 6 months. Aliment Pharmacol Ther. 2001. 15:347–354.
113. Ponce J, Argüello L, Bastida G, Ponce M, Ortiz V, Garrigues V. On-demand therapy with rabeprazole in nonerosive and erosive gastroesophageal reflux disease in clinical practice: effectiveness, health-related quality of life, and patient satisfaction. Dig Dis Sci. 2004. 49:931–936.
114. Sjöstedt S, Befrits R, Sylvan A, et al. Daily treatment with esomeprazole is superior to that taken on-demand for maintenance of healed erosive oesophagitis. Aliment Pharmacol Ther. 2005. 22:183–191.
115. Pace F, Tonini M, Pallotta S, Molteni P, Porro GB. Systematic review: maintenance treatment of gastro-oesophageal reflux disease with proton pump inhibitors taken 'on-demand'. Aliment Pharmacol Ther. 2007. 26:195–204.
116. Chung SJ, Kim SG, Jung HC, Song IS, Kim JS. Clinical practice patterns of gastroenterologists for initial and maintenance therapy in gastroesophageal reflux disease: a nationwide online survey in Korea. Korean J Gastroenterol. 2009. 54:364–370.
117. Kahrilas PJ, Quigley EM. Clinical esophageal pH recording: a technical review for practice guideline development. Gastroenterology. 1996. 110:1982–1996.
118. Vigneri S, Termini R, Leandro G, et al. A comparison of five maintenance therapies for reflux esophagitis. N Engl J Med. 1995. 333:1106–1110.
119. Miyamoto M, Manabe N, Haruma K. Efficacy of the addition of prokinetics for proton pump inhibitor (PPI) resistant non-erosive reflux disease (NERD) patients: significance of frequency scale for the symptom of GERD (FSSG) on decision of treatment strategy. Intern Med. 2010. 49:1469–1476.
120. Miyamoto M, Haruma K, Takeuchi K, Kuwabara M. Frequency scale for symptoms of gastroesophageal reflux disease predicts the need for addition of prokinetics to proton pump inhibitor therapy. J Gastroenterol Hepatol. 2008. 23:746–751.
121. Kim YS, Kim TH, Choi CS, et al. Effect of itopride, a new prokinetic, in patients with mild GERD: a pilot study. World J Gastroenterol. 2005. 11:4210–4214.
122. Futagami S, Iwakiri K, Shindo T, et al. The prokinetic effect of mosapride citrate combined with omeprazole therapy improves clinical symptoms and gastric emptying in PPI-resistant NERD patients with delayed gastric emptying. J Gastroenterol. 2010. 45:413–421.
123. Madan K, Ahuja V, Kashyap PC, Sharma MP. Comparison of efficacy of pantoprazole alone versus pantoprazole plus mosapride in therapy of gastroesophageal reflux disease: a randomized trial. Dis Esophagus. 2004. 17:274–278.
124. Miwa H, Inoue K, Ashida K, et al. Japan TREND Study Group. Randomised clinical trial: efficacy of the addition of a prokinetic, mosapride citrate, to omeprazole in the treatment of patients with non-erosive reflux disease - a double-blind, placebo-controlled study. Aliment Pharmacol Ther. 2011. 33:323–332.
125. Mainie I, Tutuian R, Shay S, et al. Acid and non-acid reflux in patients with persistent symptoms despite acid suppressive therapy: a multicentre study using combined ambulatory impedance-pH monitoring. Gut. 2006. 55:1398–1402.
126. Fass R, Shapiro M, Dekel R, Sewell J. Systematic review: proton-pump inhibitor failure in gastro-oesophageal reflux disease--where next? Aliment Pharmacol Ther. 2005. 22:79–94.
127. Fass R. Proton pump inhibitor failure--what are the therapeutic options? Am J Gastroenterol. 2009. 104:Suppl 2. S33–S38.
128. Clouse RE, Lustman PJ, Eckert TC, Ferney DM, Griffith LS. Low-dose trazodone for symptomatic patients with esophageal contraction abnormalities. A double-blind, placebo-controlled trial. Gastroenterology. 1987. 92:1027–1036.
129. Handa M, Mine K, Yamamoto H, et al. Antidepressant treatment of patients with diffuse esophageal spasm: a psychosomatic approach. J Clin Gastroenterol. 1999. 28:228–232.
130. Nojkov B, Rubenstein JH, Adlis SA, et al. The influence of co-morbid IBS and psychological distress on outcomes and quality of life following PPI therapy in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2008. 27:473–482.
131. Lundell L, Abrahamsson H, Ruth M, Rydberg L, Lönroth H, Olbe L. Long-term results of a prospective randomized comparison of total fundic wrap (Nissen-Rossetti) or semifundoplication (Toupet) for gastro-oesophageal reflux. Br J Surg. 1996. 83:830–835.
132. Johansson J, Johnsson F, Joelsson B, Florén CH, Walther B. Outcome 5 years after 360 degree fundoplication for gastro-oesophageal reflux disease. Br J Surg. 1993. 80:46–49.
133. Dent J, Brun J, Fendrick AM, et al. An evidence-based appraisal of reflux disease management - the genval workshop report. Gut. 1998. 44:S1–S16.
134. Spechler SJ, Lee E, Ahnen D, et al. Long-term outcome of medical and surgical therapies for gastroesophageal reflux disease: follow-up of a randomized controlled trial. JAMA. 2001. 285:2331–2338.
135. Catarci M, Gentileschi P, Papi C, et al. Evidence-based appraisal of antireflux fundoplication. Ann Surg. 2004. 239:325–337.
136. Galmiche JP, Hatlebakk J, Attwood S, et al. LOTUS Trial Collaborators. Laparoscopic antireflux surgery vs esomeprazole treatment for chronic GERD: the LOTUS randomized clinical trial. JAMA. 2011. 305:1969–1977.
137. Wileman SM, McCann S, Grant AM, Krukowski ZH, Bruce J. Medical versus surgical management for gastro-oesophageal reflux disease (GORD) in adults. Cochrane Database Syst Rev. 2010. (3):CD003243.
138. Campos GM, Peters JH, DeMeester TR, et al. Multivariate analysis of factors predicting outcome after laparoscopic Nissen fundoplication. J Gastrointest Surg. 1999. 3:292–300.
139. IP S, Chung M, Moorthy D, et al. Comparative effectiveness of management strategies for gastroesophageal reflux disease: update [Internet]. 2011. cited 2012 Jan 5. Rockville (MD): Agency for Healthcare Research and Quality (US);Available from: http://effectivehealthcare.ahrq.gov/ehc/products/165/781/GERD_ExecSumm.pdf.
140. Zaninotto G, Attwood SE. Surgical management of refractory gastro-oesophageal reflux. Br J Surg. 2010. 97:139–140.
141. Lundell L, Attwood S, Ell C, et al. LOTUS Trial Collaborators. Comparing laparoscopic antireflux surgery with esomeprazole in the management of patients with chronic gastro-oesophageal reflux disease: a 3-year interim analysis of the LOTUS trial. Gut. 2008. 57:1207–1213.
142. Lundell L. Complications after anti-reflux surgery. Best Pract Res Clin Gastroenterol. 2004. 18:935–945.
143. Dominitz JA, Dire CA, Billingsley KG, Todd-Stenberg JA. Complications and antireflux medication use after antireflux surgery. Clin Gastroenterol Hepatol. 2006. 4:299–305.
144. Vakil N, Shaw M, Kirby R. Clinical effectiveness of laparoscopic fundoplication in a U.S. community. Am J Med. 2003. 114:1–5.
145. Lee SK, Kim EK. Laparoscopic Nissen fundoplication in Korean patients with gastroesophageal reflux disease. Yonsei Med J. 2009. 50:89–94.
146. Arguedas MR, Heudebert GR, Klapow JC, et al. VA Cooperative Study Group. Re-examination of the cost-effectiveness of surgical versus medical therapy in patients with gastroesophageal reflux disease: the value of long-term data collection. Am J Gastroenterol. 2004. 99:1023–1028.
147. Comay D, Adam V, da Silveira EB, Kennedy W, Mayrand S, Barkun AN. The Stretta procedure versus proton pump inhibitors and laparoscopic Nissen fundoplication in the management of gastroesophageal reflux disease: a cost-effectiveness analysis. Can J Gastroenterol. 2008. 22:552–558.
148. El-Serag HB, Lee P, Buchner A, Inadomi JM, Gavin M, McCarthy DM. Lansoprazole treatment of patients with chronic idiopathic laryngitis: a placebo-controlled trial. Am J Gastroenterol. 2001. 96:979–983.
149. Sontag SJ, O'Connell S, Khandelwal S, et al. Asthmatics with gastroesophageal reflux: long term results of a randomized trial of medical and surgical antireflux therapies. Am J Gastroenterol. 2003. 98:987–999.
150. Noordzij JP, Khidr A, Evans BA, et al. Evaluation of omeprazole in the treatment of reflux laryngitis: a prospective, placebo-controlled, randomized, double-blind study. Laryngoscope. 2001. 111:2147–2151.
151. Eherer AJ, Habermann W, Hammer HF, Kiesler K, Friedrich G, Krejs GJ. Effect of pantoprazole on the course of reflux-associated laryngitis: a placebo-controlled double-blind crossover study. Scand J Gastroenterol. 2003. 38:462–467.
152. Garrigues V, Gisbert L, Bastida G, et al. Manifestations of gastroesophageal reflux and response to omeprazole therapy in patients with chronic posterior laryngitis: an evaluation based on clinical practice. Dig Dis Sci. 2003. 48:2117–2123.
153. Vaezi MF, Richter JE, Stasney CR, et al. Treatment of chronic posterior laryngitis with esomeprazole. Laryngoscope. 2006. 116:254–260.
154. Chang AB, Lasserson TJ, Kiljander TO, Connor FL, Gaffney JT, Garske LA. Systematic review and meta-analysis of randomised controlled trials of gastro-oesophageal reflux interventions for chronic cough associated with gastro-oesophageal reflux. BMJ. 2006. 332:11–17.
155. Qadeer MA, Phillips CO, Lopez AR, et al. Proton pump inhibitor therapy for suspected GERD-related chronic laryngitis: a meta-analysis of randomized controlled trials. Am J Gastroenterol. 2006. 101:2646–2654.
156. Park W, Hicks DM, Khandwala F, et al. Laryngopharyngeal reflux: prospective cohort study evaluating optimal dose of proton-pump inhibitor therapy and pretherapy predictors of response. Laryngoscope. 2005. 115:1230–1238.
157. Charbel S, Khandwala F, Vaezi MF. The role of esophageal pH monitoring in symptomatic patients on PPI therapy. Am J Gastroenterol. 2005. 100:283–289.
158. Mittal RK, Holloway R, Dent J. Effect of atropine on the frequency of reflux and transient lower esophageal sphincter relaxation in normal subjects. Gastroenterology. 1995. 109:1547–1554.
159. Lidums I, Lehmann A, Checklin H, Dent J, Holloway RH. Control of transient lower esophageal sphincter relaxations and reflux by the GABA(B) agonist baclofen in normal subjects. Gastroenterology. 2000. 118:7–13.
160. Hirsch DP, Tytgat GN, Boeckxstaens GE. Is glutamate involved in transient lower esophageal sphincter relaxations? Dig Dis Sci. 2002. 47:661–666.
161. Frisby CL, Mattsson JP, Jensen JM, Lehmann A, Dent J, Blackshaw LA. Inhibition of transient lower esophageal sphincter relaxation and gastroesophageal reflux by metabotropic glutamate receptor ligands. Gastroenterology. 2005. 129:995–1004.
162. Scarpellini E, Blondeau K, Boecxstaens V, et al. Effect of rimonabant on oesophageal motor function in man. Aliment Pharmacol Ther. 2011. 33:730–737.
163. Boeckxstaens GE, Rydholm H, Lei A, Adler J, Ruth M. Effect of lesogaberan, a novel GABA(B)-receptor agonist, on transient lower oesophageal sphincter relaxations in male subjects. Aliment Pharmacol Ther. 2010. 31:1208–1217.
164. Boeckxstaens GE, Beaumont H, Mertens V, et al. Effects of lesogaberan on reflux and lower esophageal sphincter function in patients with gastroesophageal reflux disease. Gastroenterology. 2010. 139:409–417.
165. Vela MF, Tutuian R, Katz PO, Castell DO. Baclofen decreases acid and non-acid post-prandial gastro-oesophageal reflux measured by combined multichannel intraluminal impedance and pH. Aliment Pharmacol Ther. 2003. 17:243–251.
166. Zhang Q, Lehmann A, Rigda R, Dent J, Holloway RH. Control of transient lower oesophageal sphincter relaxations and reflux by the GABA(B) agonist baclofen in patients with gastro-oesophageal reflux disease. Gut. 2002. 50:19–24.
167. Tytgat GN. Clinical efficacy of sucralfate in reflux esophagitis. Comparison with cimetidine. Am J Med. 1987. 83:38–42.
168. Katada K, Yoshida N, Isozaki Y, et al. Prevention by rebamipide of acute reflux esophagitis in rats. Dig Dis Sci. 2005. 50:Suppl 1. S97–S103.
169. Yoshida N, Kamada K, Tomatsuri N, et al. Management of recurrence of symptoms of gastroesophageal reflux disease: synergistic effect of rebamipide with 15 mg lansoprazole. Dig Dis Sci. 2010. 55:3393–3398.
170. Adachi K, Furuta K, Miwa H, et al. A study on the efficacy of rebamipide for patients with proton pump inhibitor-refractory non-erosive reflux disease. Dig Dis Sci. 2012. 57:1609–1617.
TOOLS
Similar articles